Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro.

We examined the relationship between (18)F- labeled 2-fluro-2-deoxy-d-glucose (FDG) uptake, and expression of glucose transporters (GLUTs) in two human small-cell lung cancer (SCLC) lines CPH 54A and CPH 54B. Changes in the expression of GLUTs and vascular endothelial growth factor (VEGF) during 12-, 18-, and 24 hours of severe hypoxia in vivo (xenografts) and in vitro (cell cultures) were recorded for both tumor lines. The two SCLC lines are subpopulations of the same patient tumor. In spite of their common genomic origin they represent consistently different metabolic and microenvironmental phenotypes as well as treatment sensitivities. There were higher levels of Glut-1 protein in 54B and a correspondingly higher FDG uptake in this tumor line (P<.001). During hypoxia a significant upregulation of in VEGF mRNA, GLUT-1 mRNA, and Glut-1 and -3 protein occurred with a distinctly different time course in the two cell lines. A similar co-upregulation of GLUT and VEGF was seen in hypoxic tumors of both lines. There were no significant changes of HIF-1alpha mRNA during hypoxia in either of the cell lines. A more detailed understanding of such correlations between glucose metabolism, angiogenesis, and microenvironmental phenotype of tumors, by positron emission tomography (PET) and molecular techniques might further sophisticate our interpretation of glycolytic predominance in tumors as seen by 18FFDG PET.

[1]  Andrew L. Kung,et al.  Suppression of tumor growth through disruption of hypoxia-inducible transcription , 2000, Nature Medicine.

[2]  T. Suzuki,et al.  Enhanced expression of glucose transporter GLUT3 in tumorigenic HeLa cell hybrids associated with tumor suppressor dysfunction. , 1999, European journal of biochemistry.

[3]  L. Huang,et al.  Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .

[4]  G. Semenza,et al.  Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  W C Eckelman,et al.  Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. , 1999, Cancer research.

[6]  G. Breier,et al.  Hypoxia-induced Transcriptional Activation and Increased mRNA Stability of Vascular Endothelial Growth Factor in C6 Glioma Cells (*) , 1995, The Journal of Biological Chemistry.

[7]  F. Ismail-Beigi,et al.  Dual Control of glut1 Glucose Transporter Gene Expression by Hypoxia and by Inhibition of Oxidative Phosphorylation* , 1997, The Journal of Biological Chemistry.

[8]  P. Kristjansen,et al.  Different energy metabolism in two human small cell lung cancer subpopulations examined by 31P magnetic resonance spectroscopy and biochemical analysis in vivo and in vitro. , 1991, Cancer research.

[9]  G. Semenza,et al.  General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Neeman,et al.  Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes , 1995, Molecular and cellular biology.

[12]  G. Semenza,et al.  Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. , 1993, The Journal of biological chemistry.

[13]  H. Poulsen,et al.  Cellular radiosensitivity of small-cell lung cancer cell lines. , 1997, International journal of radiation oncology, biology, physics.

[14]  Kazutomo Inoue,et al.  Over-expression of facilitative glucose transporter genes in human cancer. , 1990, Biochemical and biophysical research communications.

[15]  P. Kristjansen,et al.  Early effects of radiotherapy in small cell lung cancer xenografts monitored by 31P magnetic resonance spectroscopy and biochemical analysis. , 1990, Cancer research.

[16]  N. Tamaki,et al.  Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  F. Ismail-Beigi,et al.  Induction of GLUT1 mRNA in response to inhibition of oxidative phosphorylation. , 1993, The American journal of physiology.

[18]  H. Hansen,et al.  Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M. Horsman,et al.  The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo. , 1999, International journal of radiation biology.

[20]  M. Younes,et al.  Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. , 1996, Cancer research.

[21]  H. Malcolm Hudson,et al.  Accelerated image reconstruction using ordered subsets of projection data , 1994, IEEE Trans. Medical Imaging.

[22]  M. Gassmann,et al.  Hypoxia-inducible factor-1 alpha is regulated at the post-mRNA level. , 1997, Kidney international.

[23]  M. Clerici,et al.  Growth kinetics and in vivo radiosensitivity in nude mice of two subpopulations derived from a single human small cell carcinoma of the lung. , 1986, European journal of cancer & clinical oncology.

[24]  K P Fung,et al.  Increases in mRNA levels of glucose transporters types 1 and 3 in Ehrlich ascites tumor cells during tumor development , 1997, Journal of cellular biochemistry.

[25]  R. Jain,et al.  Intratumor pharmacokinetics, flow resistance, and metabolism during gemcitabine infusion in ex vivo perfused human small cell lung cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  D. Livingston,et al.  Activation of Hypoxia-inducible Transcription Factor Depends Primarily upon Redox-sensitive Stabilization of Its α Subunit* , 1996, The Journal of Biological Chemistry.

[27]  D. Lee,et al.  Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  W. Hiddemann,et al.  Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. , 1997, Anticancer research.

[29]  P. Kristjansen.  Pathophysiology of human tumor xenografts. Aspects of metabolism, physiology, and pharmacokinetics in heterotransplanted human lung and colon tumors. , 1997, Danish medical bulletin.

[30]  Yuichi Makino,et al.  Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway* , 1999, The Journal of Biological Chemistry.

[31]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[32]  J. Simons,et al.  Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. , 1999, Biochemical and biophysical research communications.

[33]  Rakesh K. Jain,et al.  Spatial Heterogeneity in Tumor Perfusion Measured with Functional Computed Tomography at 0.05 µl Resolution , 1994 .

[34]  R L Wahl,et al.  Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  N. Sadato,et al.  The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. , 1998, Nuclear medicine and biology.